Dergiler / Turkish Journal of Medical Sciences / 2016 / Cilt: 46 - Sayı: 4

Plasma lipoprotein(a) levels are associated with the severity of coronary heart disease in Han Chinese people

Sayfa
1033–1041
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Our data indicate that Lp(a) might be a useful marker in predicting the severity of coronary heart disease.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: The aim of this study was to investigate the association of lipoprotein(a) [Lp(a)] with the severity of coronary heart disease (CHD) in Han Chinese people.
📊
Temel Bulgular & Veri:Results: The levels of Lp(a), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), and apolipoprotein (apo) B100 increased, while high-density lipoprotein cholesterol (HDL-C) and apoAI decreased significantly with the number of stenotic vessels.
💡
Sonuç & Katkı:Conclusion: Our data indicate that Lp(a) might be a useful marker in predicting the severity of coronary heart disease.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: The aim of this study was to investigate the association of lipoprotein(a) [Lp(a)] with the severity of coronary heart disease (CHD) in Han Chinese people. Materials and methods: Six hundred and seventy-nine patients with angiographically defined CHD were enrolled in this cross-sectional study. Fasting lipids were measured, and the severity of CHD was quantitatively assessed for each patient according to the number of stenotic coronary branches and the Gensini scoring system. Results: The levels of Lp(a), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), and apolipoprotein (apo) B100 increased, while high-density lipoprotein cholesterol (HDL-C) and apoAI decreased significantly with the number of stenotic vessels. The levels of Lp(a) increased and HDL-C and apoAI decreased significantly with the Gensini scores. The logistic regression analyses showed that Lp(a) and HDL-C were independently associated with the number of stenotic coronary vessels after adjusting for age, weight, body mass index, sex, smoking, alcohol consumption, hypertension, diabetes, triglycerides, TC, LDL-C, VLDL-C, apoAI, and apoB100. However, only Lp(a) was independently associated with the Gensini scores after adjustment. Conclusion: Our data indicate that Lp(a) might be a useful marker in predicting the severity of coronary heart disease.

🔖

Bu Makaleye Atıf Yap

FENG, Y., YANG, Y., ZHANG, X., LI, P., ZHU, L., SONG, Y., LU, Z., ZHU, L., OUYANG, X., YE, W., ZHANG, X. (2022). Plasma lipoprotein(a) levels are associated with the severity of coronary heart disease in Han Chinese people. Turkish Journal of Medical Sciences, Cilt: 46 - Sayı: 4, 1033–1041. https://ajindex.com/articles/610647

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. Circulation 2005; 112: 3547-3553
  2. Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world. Health Aff (Millwood) 2007; 26: 13-24
  3. Hu SS, Kong LZ, Gao RL, Zhu ML, Wang W, Wang YJ, Wu ZS, Chen WW, Liu MB; Editorial Board. Outline of the report on cardiovascular disease in China, 2010. Biomed Environ Sci 2012; 25: 251-256
  4. Panwar RB, Gupta R, Gupta BK, Raja S, Vaishnav J, Khatri M, Agrawal A. Atherothrombotic risk factors & premature coronary heart disease in India: a case-control study. Indian J Med Res 2011; 134: 26-32
  5. Jomini V, Oppliger-Pasquali S, Wietlisbach V, Rodondi N, Jotterand V, Paccaud F, Darioli R, Nicod P, Mooser V. Contribution of major cardiovascular risk factors to familial premature coronary artery disease: the GENECARD project. J Am Coll Cardiol 2002; 40: 676-684
  6. Wilson PW. CETP genes, metabolic effects, and coronary disease risk. JAMA 2008; 299: 2795-2796
  7. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952
  8. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421
  9. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S1-45
  10. Berg K. A new serum type system in man--the LP system. Acta Pathol Microbiol Scand 1963; 59: 369-382
  11. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412- 423
  12. Bennet A, Di Angelantonio E, Erqou S, Eiri